Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer’s Aβ peptides
- 431 Downloads
Nucleation-dependent protein aggregation (“seeding”) and amyloid fibril-free formation of soluble SDS-resistant oligomers (“oligomerization”) by hydrophobic interaction is an in vitro model thought to propagate β-amyloid (Aβ) deposition, accumulation, and incur neurotoxicity and synaptotoxicity in Alzheimer’s disease (AD), and other amyloid-associated neurodegenerative diseases. However, Aβ is a high-affinity metalloprotein that aggregates in the presence of biometals (zinc, copper, and iron), and neocortical Aβ deposition is abolished by genetic ablation of synaptic zinc in transgenic mice. We now present in vitro evidence that trace (≤0.8 µM) levels of zinc, copper, and iron, present as common contaminants of laboratory buffers and culture media, are the actual initiators of the classic Aβ1–42-mediated seeding process and Aβ oligomerization. Replicating the experimental conditions of earlier workers, we found that the in vitro precipitation and amyloidosis of Aβ1–40 (20 µM) initiated by Aβ1–42 (2 µM) were abolished by chelation of trace metal contaminants. Further, metal chelation attenuated formation of soluble Aβ oligomers from a cell-free culture medium. These data suggest that protein self-assembly and oligomerization are not spontaneous in this system as previously thought, and that there may be an obligatory role for metal ions in initiating Aβ amyloidosis and oligomerization.
KeywordsAβ amyloid Aβ oligomerization Alzheimer’s disease Metal chelator Trace metal contaminants
Dulbecco’s modified Eagle’s medium
ion coupled plasma-mass spectroscopy
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
X.H. was supported by a NRSA award (5F32AG05782) from the NIH, and is a recipient of an NIH Career Development grant (5K01MH02001) and an AFAR grant. A.I.B. was supported by funds from the NIA (5R01AG12685), the American Health Assistance Foundation, the Alzheimer Association, and the Neuroscience Research and Education Foundation. R.E.T. is an Ellison Medical Foundation Senior Scholar.
- 4.Suzuki A, Takashima S, Mizuguchi M, Kato M, Kunishita T, Tabira T (1994) Tohoku J Exp Med 174:181–187Google Scholar
- 28.McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Ann Neurol 46:860–866Google Scholar
- 40.Bush AI, Moir RD, Rosenkranz KM, Tanzi RE (1995) Science 268:1921–1923Google Scholar
- 42.Huang X, Atwood CS, Goldstein LE, Hartshorn MA, Saunders AJ, Moir RD, Tanzi RE, Bush AI (1999) In: Iqbal K, Swaab DF, Winblad B, Wisniewski HM (eds) Alzheimer’s disease and related disorders: etiology, pathogenesis and therapeutics. Wiley, Chichester, UK, pp 383–390Google Scholar
- 48.Grundke-Iqbal I, Fleming J, Tung YC, Lassmann H, Iqbal K, Joshi JG (1990) Acta Neuropathol (Berlin) 81:105–110Google Scholar